Insights into medicinal attributes of imidazo[1,2-a]pyridine derivatives as anticancer agents.

Kumar, A; Sharma, V; Behl, T; Ganesan, S; Nathiya, D; Gulati, M; Khalid, M; Elossaily, GM; Chigurupati, S; Sachdeva, M

Insights into medicinal attributes of imidazo[1,2-a]pyridine derivatives as anticancer agents.

Kumar, A Sharma, V Behl, T Ganesan, S Nathiya, D Gulati, M Khalid, M Elossaily, GM Chigurupati, S Sachdeva, M

Permalink

Publisher:: Wiley
Publication Type:: Journal Article
Citation:: Arch Pharm (Weinheim), 2024, 357, (11), pp. e2400402
Issue Date:: 2024-11

Closed Access

	Filename	Description	Size
	fenrg-12-1355686.pdf	Published version	1.54 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Kumar, A
dc.contributor.author	Sharma, V
dc.contributor.author	Behl, T
dc.contributor.author	Ganesan, S
dc.contributor.author	Nathiya, D
dc.contributor.author	Gulati, M
dc.contributor.author	Khalid, M
dc.contributor.author	Elossaily, GM
dc.contributor.author	Chigurupati, S
dc.contributor.author	Sachdeva, M
dc.date.accessioned	2025-05-06T05:47:22Z
dc.date.available	2024-08-13
dc.date.available	2025-05-06T05:47:22Z
dc.date.issued	2024-11
dc.identifier.citation	Arch Pharm (Weinheim), 2024, 357, (11), pp. e2400402
dc.identifier.issn	0365-6233
dc.identifier.issn	1521-4184
dc.identifier.uri	http://hdl.handle.net/10453/187204
dc.description.abstract	Cancer ranks among the most life-threatening diseases worldwide and is continuously affecting all age groups. Consequently, many research studies are being carried out to develop new cancer treatments, but many of them experience resistance and cause severe toxicity to the patients. Therefore, there is a continuous need to design novel anticancer agents that are target-based, have a higher potency, and have minimal toxicity. The imidazo[1,2-a]pyridine (IP) pharmacophore has been found to be a prominent moiety in the field of medicinal chemistry due to its vast biological properties. Also, it holds immense potential for combating cancer with minimal side effects, depending on the substitution patterns of the core structure. IPs exhibit significant capability in regulating various cellular pathways, offering possibilities for targeted anticancer effects. The present review summarizes the anticancer profile of numerous IP derivatives synthesized and developed by various researchers from 2016 till now, as inhibitors of phosphoinositide-3-kinase/mammalian target of rapamycin (PI3K/mTOR), protein kinase B/mammalian target of rapamycin (Akt/mTOR), aldehyde dehydrogenase (ALDH), and tubulin polymerization. This review provides a comprehensive analysis of the anticancer activity afforded by the discussed IP compounds, emphasizing the structure-activity-relationships (SARs). The aim is also to underscore the potential therapeutic future of the IP moiety as a potent partial structure for upcoming cancer drug development and to aid researchers in the field of rational drug design.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Wiley
dc.relation.ispartof	Arch Pharm (Weinheim)
dc.relation.isbasedon	10.1002/ardp.202400402
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	0304 Medicinal and Biomolecular Chemistry, 1115 Pharmacology and Pharmaceutical Sciences
dc.subject.classification	Medicinal & Biomolecular Chemistry
dc.subject.classification	3214 Pharmacology and pharmaceutical sciences
dc.subject.classification	3404 Medicinal and biomolecular chemistry
dc.subject.mesh	Humans
dc.subject.mesh	Antineoplastic Agents
dc.subject.mesh	Pyridines
dc.subject.mesh	Structure-Activity Relationship
dc.subject.mesh	Imidazoles
dc.subject.mesh	Neoplasms
dc.subject.mesh	Animals
dc.subject.mesh	Molecular Structure
dc.subject.mesh	Animals
dc.subject.mesh	Humans
dc.subject.mesh	Neoplasms
dc.subject.mesh	Imidazoles
dc.subject.mesh	Pyridines
dc.subject.mesh	Antineoplastic Agents
dc.subject.mesh	Molecular Structure
dc.subject.mesh	Structure-Activity Relationship
dc.subject.mesh	Humans
dc.subject.mesh	Antineoplastic Agents
dc.subject.mesh	Pyridines
dc.subject.mesh	Structure-Activity Relationship
dc.subject.mesh	Imidazoles
dc.subject.mesh	Neoplasms
dc.subject.mesh	Animals
dc.subject.mesh	Molecular Structure
dc.title	Insights into medicinal attributes of imidazo[1,2-a]pyridine derivatives as anticancer agents.
dc.type	Journal Article
utslib.citation.volume	357
utslib.location.activity	Germany
utslib.for	0304 Medicinal and Biomolecular Chemistry
utslib.for	1115 Pharmacology and Pharmaceutical Sciences
pubs.organisational-group	University of Technology Sydney
pubs.organisational-group	University of Technology Sydney/Faculty of Health
utslib.copyright.status	closed_access	*
dc.date.updated	2025-05-06T05:47:20Z
pubs.issue	11
pubs.publication-status	Published
pubs.volume	357
utslib.citation.issue	11

Abstract:

Cancer ranks among the most life-threatening diseases worldwide and is continuously affecting all age groups. Consequently, many research studies are being carried out to develop new cancer treatments, but many of them experience resistance and cause severe toxicity to the patients. Therefore, there is a continuous need to design novel anticancer agents that are target-based, have a higher potency, and have minimal toxicity. The imidazo[1,2-a]pyridine (IP) pharmacophore has been found to be a prominent moiety in the field of medicinal chemistry due to its vast biological properties. Also, it holds immense potential for combating cancer with minimal side effects, depending on the substitution patterns of the core structure. IPs exhibit significant capability in regulating various cellular pathways, offering possibilities for targeted anticancer effects. The present review summarizes the anticancer profile of numerous IP derivatives synthesized and developed by various researchers from 2016 till now, as inhibitors of phosphoinositide-3-kinase/mammalian target of rapamycin (PI3K/mTOR), protein kinase B/mammalian target of rapamycin (Akt/mTOR), aldehyde dehydrogenase (ALDH), and tubulin polymerization. This review provides a comprehensive analysis of the anticancer activity afforded by the discussed IP compounds, emphasizing the structure-activity-relationships (SARs). The aim is also to underscore the potential therapeutic future of the IP moiety as a potent partial structure for upcoming cancer drug development and to aid researchers in the field of rational drug design.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/187204